

# Journal of Visualized Experiments

## Using in vitro fluorescence resonance energy transfer to study the dynamics of protein complexes at a millisecond time scale

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59038R2
Full Title:	Using in vitro fluorescence resonance energy transfer to study the dynamics of protein complexes at a millisecond time scale
Keywords:	Protein complex; binding kinetics; protein labeling; in vitro FRET; stopped-flow fluorescence; protein exchange
Corresponding Author:	Xing Liu Purdue University West Lafayette, IN UNITED STATES
Corresponding Author's Institution:	Purdue University
Corresponding Author E-Mail:	xingliu@purdue.edu
Order of Authors:	Melaku Garsamo Yun Zhou Xing Liu
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	West Lafayette, IN, USA

**TITLE:**

**Using *In Vitro* Fluorescence Resonance Energy Transfer to Study the Dynamics Of Protein Complexes at a Millisecond Time Scale**

**AUTHORS AND AFFILIATIONS:**

Melaku Garsamo<sup>1</sup>, Yun Zhou<sup>2,3</sup>, Xing Liu<sup>1,3</sup>

<sup>1</sup>Department of Biochemistry, Purdue University, West Lafayette, IN, USA

<sup>2</sup>Department of Botany and Plant Pathology, Purdue University, West Lafayette, IN, USA

<sup>3</sup>Center for Plant Biology, Purdue University, West Lafayette, IN, USA

**Corresponding Author:**

Xing Liu (xingliu@purdue.edu)

Tel: (765)-494-1793

**Email Addresses of Co-authors:**

Melaku Garsamo (mgarsamo@purdue.edu)

Yun Zhou (zhouyun@purdue.edu)

**KEYWORDS:**

protein complex, binding kinetics, protein labeling, *in vitro* FRET, stopped-flow fluorescence, protein exchange

**SUMMARY:**

Protein-protein interactions are critical for biological systems, and studies of the binding kinetics provide insights into the dynamics and function of protein complexes. We describe a method that quantifies the kinetic parameters of a protein complex using fluorescence resonance energy transfer and the stopped-flow technique.

**ABSTRACT:**

Proteins are the primary operators of biological systems, and they usually interact with other macro- or small molecules to carry out their biological functions. Such interactions can be highly dynamic, meaning the interacting subunits are constantly associated and dissociated at certain rates. While measuring the binding affinity using techniques such as quantitative pull-down reveals the strength of the interaction, studying the binding kinetics provides insights on how fast the interaction occurs and how long each complex can exist. Furthermore, measuring the kinetics of an interaction in the presence of an additional factor, such as a protein exchange factor or a drug, helps reveal the mechanism by which the interaction is regulated by the other factor, providing important knowledge for the advancement of biological and medical research. Here, we describe a protocol for measuring the binding kinetics of a protein complex that has a high intrinsic association rate and can be dissociated quickly by another protein. The method uses fluorescence resonance energy transfer to report the formation of the protein complex *in vitro*, and it enables monitoring the fast association and dissociation of the complex in real time on a stopped-flow fluorimeter. Using this assay, the association and dissociation rate constants of the protein complex are quantified.

## INTRODUCTION:

Biological activities are ultimately carried out by proteins, most of which interact with others for proper biological functions. Using a computational approach, the total amount of protein-protein interactions in human is estimated to be  $\sim 650,000$ <sup>1</sup>, and disruption of these interactions often leads to diseases<sup>2</sup>. Due to their essential roles in controlling cellular and organismal processes, numerous methods have been developed to study protein-protein interactions, such as yeast-two-hybrid, bimolecular fluorescence complementation, split-luciferase complementation, and co-immunoprecipitation assay<sup>3</sup>. While these methods are good at discovering and confirming protein-protein interactions, they are usually non-quantitative and thus provide limited information about the affinity between the interacting protein partners. Quantitative pull-downs can be used to measure the binding affinity (e.g., the dissociation constant  $K_d$ ), but it does not measure the kinetics of the binding, nor can it be applied when the  $K_d$  is very low due to an inadequate signal-to-noise ratio<sup>4</sup>. Surface plasmon resonance (SPR) spectroscopy quantifies the binding kinetics, but it requires a specific surface and immobilization of one reactant on the surface, which can potentially change the binding property of the reactant<sup>5</sup>. Moreover, it is difficult for SPR to measure fast association and dissociation rates<sup>5</sup>, and it is not appropriate to use SPR to characterize the event of exchanging protein subunits in a protein complex. Here, we describe a method that allows measuring rates of protein complex assembly and disassembly at a millisecond time scale. This method was essential for determining the role of Cullin-associated-Nedd8-dissociated protein 1 (Cand1) as the F-box protein exchange factor<sup>6,7</sup>.

Cand1 regulates the dynamics of Skp1•Cul1•F-box protein (SCF) E3 ligases, which belong to the large family of Cullin-RING ubiquitin ligases. SCFs consist of the cullin Cul1, which binds the RING domain protein Rbx1, and an interchangeable F-box protein, which recruits substrates and binds Cul1 through the adaptor protein Skp1<sup>8</sup>. As an E3 ligase, SCF catalyzes the conjugation of ubiquitin to its substrate, and it is activated when the substrate is recruited by the F-box protein, and when Cul1 is modified by the ubiquitin-like protein Nedd8<sup>9</sup>. Cand1 binds unmodified Cul1, and upon binding, it disrupts both the association of Skp1•F-box protein with Cul1 and the conjugation of Nedd8 to Cul1<sup>10–13</sup>. As a result, Cand1 appeared to be an inhibitor of SCF activity in vitro, but Cand1 deficiency in organisms caused defects that suggests a positive role of Cand1 in regulating SCF activities in vivo<sup>14–17</sup>. This paradox was finally explained by a quantitative study that revealed the dynamic interactions among Cul1, Cand1, and Skp1•F-box protein. Using fluorescence resonance energy transfer (FRET) assays that detect the formation of the SCF and Cul1•Cand1 complexes, the association and dissociation rate constants ( $k_{on}$  and  $k_{off}$ , respectively) were measured individually. The measurements revealed that both Cand1 and Skp1•F-box protein form extremely tight complex with Cul1, but the  $k_{off}$  of SCF is dramatically increased by Cand1 and the  $k_{off}$  of Cul1•Cand1 is dramatically increased by Skp1•F-box protein<sup>6,7</sup>. These results provide the initial and critical support for defining the role of Cand1 as a protein exchange factor, which catalyzes the formation of new SCF complexes through recycling Cul1 from the old SCF complexes.

Here, we present the procedure of developing and using the FRET assay to study the dynamics of the Cul1•Cand1 complex<sup>7</sup>, and the same principle can be applied to study the dynamics of various

biomolecules. FRET occurs when a donor is excited with the appropriate wavelength, and an acceptor with excitation spectrum overlapping the donor emission spectrum is present within a distance of 10–100 Å. The excited state is transferred to the acceptor, thereby decreasing the donor intensity and increasing the acceptor intensity<sup>18</sup>. The efficiency of FRET ( $E$ ) depends on both the Förster radius ( $R_0$ ) and the distance between the donor and acceptor fluorophores ( $r$ ), and is defined by:  $E = R_0^6 / (R_0^6 + r^6)$ . The Förster radius ( $R_0$ ) depends on a few factors, including the dipole angular orientation, the spectral overlap of the donor-acceptor pair, and the solution used<sup>19</sup>. To apply the FRET assay on a stopped-flow fluorimeter, which monitors the change of the donor emission in real-time and enables measurements of fast  $k_{on}$  and  $k_{off}$ , it is necessary to establish efficient FRET that results in a significant reduction of donor emission. Therefore, designing efficient FRET by choosing the appropriate pair of fluorescent dyes and sites on the target proteins to attach the dyes is important and will be discussed in this protocol.

## PROTOCOL:

### 1. Design the FRET assay.

1.1. Download the structure file of the Cul1•Cand1 complex from the Protein Data Bank (file 1U6G).

1.2. View the structure of the Cul1•Cand1 complex in PyMOL.

1.3. Use the **Measurement** function under the **Wizard** menu of PyMOL to estimate the distance between the first amino acid of Cand1 and the last amino acid of Cul1 (**Figure 1**).

1.4. Load the online spectra viewer (see **Table of Materials**) and view the excitation and emission spectra of 7-amino-4-methylcoumarin (AMC) and FIAsh simultaneously (**Figure 2**). Note that AMC is the FRET donor and FIAsh is the FRET acceptor.

### 2. Preparation of Cul1<sup>AMC</sup>•Rbx1, the FRET donor protein

2.1. Construct plasmids for expressing human Cul1<sup>sortase</sup>•Rbx1 in E. coli cells. Note that the two plasmids co-expressing human Cul1•Rbx1 in E. coli cells are described in detail in a previous report<sup>20</sup>.

2.1.1. Add a DNA sequence coding “LPETGGHHHHH” (sortase-His<sub>6</sub> tag) to the 3’ end of Cul1 coding sequence through standard PCR and cloning methods<sup>21,22</sup>.

2.1.2. Sequence the new plasmid to confirm the gene insert is accurate.

2.2. Co-express Cul1<sup>sortase</sup>•Rbx1 in E. coli cells. The method is derived from a previous report<sup>20</sup>.

2.2.1. Mix 100 ng each of the two plasmids with BL21 (DE3) chemically competent cells for co-transformation using the heat shock method<sup>23</sup>. Grow cells on LB agar plate containing 100 µg/mL ampicillin and 34 µg/mL chloramphenicol at 37 °C overnight.

2.2.2. Inoculate 50 mL of LB culture with freshly transformed colonies and grow overnight at 37 °C with 250 rpm shaking. This gives a starter culture.

2.2.3. Inoculate 6 flasks, each with 1 L of LB medium, with 5 mL starter culture each and grow at 37 °C with 250 rpm shaking until the OD<sub>600</sub> is ~1.0. Cool the culture to 16 °C and add isopropyl-β-D-thiogalactoside (IPTG) to 0.4 mM. Keep the culture at 16 °C overnight with 250 rpm shaking.

2.2.4. Harvest the E. coli cells through centrifugation at 5,000 x g for 15 min and collect cell pellets in 50 mL conical tubes.

NOTE: The cell pellets can be processed for protein purification or be frozen at -80 °C before proceeding to the protein purification steps.

### 2.3. Purification of the Cul1<sup>sortase</sup>•Rbx1 complex. This method is derived from a previous report<sup>20</sup>.

2.3.1. Add 50 mL of lysis buffer (30 mM Tris-HCl, 200 mM NaCl, 5 mM DTT, 10% glycerol, 1 tablet of protease inhibitor cocktail, pH 7.6) to the pellet of E. coli cells expressing Cul1<sup>sortase</sup>•Rbx1.

2.3.2. Lyse the cells on ice with sonication at 50% amplitude. Alternate between 1-second ON and 1-second OFF and run for 3 min.

2.3.3. Repeat step 2.3.2 2-3x.

2.3.4. Transfer the cell lysate into a 50-mL centrifugation tube and remove the cell debris by centrifugation at 25,000 x g for 45 min.

2.3.5. Incubate the clear cell lysate with 5 mL of glutathione beads at 4 °C for 2 h.

2.3.6. Centrifuge the beads-lysate mixture at 1,500 x g for 2 min at 4 °C. Remove the supernatant.

2.3.7. Wash the beads with 5 mL of lysis buffer (with no protease inhibitors) and remove the supernatant after centrifugation at 1,500 x g for 2 min at 4 °C.

2.3.8. Repeat step 2.3.7 2x.

2.3.9. Add 3 mL of lysis buffer to the washed beads and transfer the bead slurry into an empty column.

2.3.10. Add 5 mL of elution buffer (50 mM Tris-HCl, 200 mM NaCl, 10 mM reduced glutathione, pH 8.0) into the column. Incubate for 10 min and collect the eluate.

2.3.11. Repeat step 2.3.10 3-4x.

2.3.12. Add 200  $\mu$ L of 5 mg/mL thrombin (see **Table of Materials**) to the eluate from the glutathione beads and incubate overnight at 4  $^{\circ}$ C.

NOTE: The protocol can be paused here.

2.3.13. Dilute the protein sample with Buffer A (25 mM HEPES, 1 mM DTT, 5% glycerol, pH 6.5) threefold.

2.3.14. Equilibrate a cation exchange chromatography column (see **Table of Materials**) on an FPLC system with Buffer A.

2.3.15. Load the protein sample to the equilibrated cation exchange chromatography column at a 0.5 mL/min flow rate.

2.3.16. Elute the protein with a gradient of NaCl in 40 mL by mixing Buffer A and 0 to 50% Buffer B (25 mM HEPES, 1 M NaCl, 1 mM DTT, 5% glycerol, pH 6.5) at a 1 mL/min flow rate.

2.3.17. Check the eluted protein in different fractions using SDS-PAGE<sup>24</sup>.

NOTE: The protocol can be paused here.

2.3.18. Pool the eluate fractions containing Cul1<sup>sortase</sup>•Rbx1.

2.3.19. Concentrate the pooled Cul1<sup>sortase</sup>•Rbx1 sample to 2.5 mL by passing the buffer through an ultrafiltration membrane (30 kDa cutoff).

2.4. Add AMC to the C-terminus of Cul1 through sortase-mediated transpeptidation<sup>21,22</sup>.

2.4.1. Change the buffer in the Cul1<sup>sortase</sup>•Rbx1 sample to the sortase buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM CaCl<sub>2</sub>, pH 7.5) using a desalting column (see **Table of Materials**).

2.4.1.1. Equilibrate a desalting column with 25 mL of sortase buffer.

2.4.1.2. Load 2.5 mL of Cul1<sup>sortase</sup>•Rbx1 sample into the column. Discard the flow-through.

2.4.1.3. Elute the sample with 3.5 mL of sortase buffer. Collect the flow-through.

2.4.2. In 900  $\mu$ L of the Cul1<sup>sortase</sup>•Rbx1 solution in the sortase buffer, add 100  $\mu$ L of 600  $\mu$ M purified sortase A solution and 10  $\mu$ L of 25 mM GGGG<sup>AMC</sup> peptide. Incubate the reaction mixture at 30  $^{\circ}$ C in the dark overnight. Note that this step will generate Cul1<sup>AMC</sup>•Rbx1.

CAUTION: Fluorescent dyes are sensitive to light, so avoid exposing them to ambient light during the protein and sample preparation as much as possible.

NOTE: The protocol can be paused here.

2.4.3. Add 50  $\mu$ L of Ni-NTA agarose beads to the reaction mixture and incubate at room temperature for 30 min.

2.4.4. Pellet the Ni-NTA agarose beads by centrifugation at 5,000  $\times g$  for 2 min and collect the supernatant.

2.4.5. Equilibrate a size exclusion chromatography column (see **Table of Materials**) with buffer (30 mM Tris-HCl, 100 mM NaCl, 1 mM DTT, 10% glycerol) on the FPLC system.

2.4.6. Load all the Cul1<sup>AMC</sup>•Rbx1 sample on the size exclusion chromatography column. Elute with 1.5x column volume of buffer.

2.4.7. Check the eluate fractions by SDS-PAGE<sup>24</sup>.

2.4.8. Pool the eluate fractions containing Cul1<sup>AMC</sup>•Rbx1.

2.4.9. Measure the protein concentration using its absorbance at 280 nm with a spectrophotometer.

2.4.10. Aliquot the protein solution and store at -80 °C.

NOTE: The protocol can be paused here.

### 3. Preparation of FIA<sup>SH</sup>Cand1, the FRET acceptor protein

NOTE: Most of steps in this part are the same as Step 2. Conditions that differ are described in detail below.

3.1. Construct the plasmid for expressing human TetraCysCand1 in E. coli cells.

3.1.1. Add DNA sequence coding “CCPGCCGSG” (tetracysteine/TetraCys tag) before the 15<sup>th</sup> amino acid of Cand1 through regular PCR<sup>25</sup> (primer sequences: TGCTGTCCGGGCTGCTGCGGCAGCGGCATGACATCCAGCGACAAGGACTTTAG; CTAAGTAGTGTCCATTGATTCCAAG).

3.1.2. Insert the PCR product into a pGEX-4T-2 vector. Sequence the plasmid to confirm the gene insert is accurate and in frame.

3.2. Express TetraCysCand1 in E. coli cells in the same way as step 2.2, except that the plasmid is transformed into Rosetta competent cells.

3.3. Purification of TetraCysCand1 from the E. coli cells.

3.3.1. Lyse the E. coli cell pellets and extract <sup>TetraCys</sup>Cand1 using glutathione beads. These steps are the same as steps 2.3.1–2.3.12.

3.3.2. Dilute the protein eluate from the glutathione beads with Buffer C (50 mM Tris-HCl, 1 mM DTT, 5% glycerol, pH 7.5) by three folds. Equilibrate an anion exchange chromatography column (see **Table of Materials**) on the FPLC system with Buffer C and load the diluted protein sample at a 0.5 mL/min flow rate.

3.3.3. Elute the protein with a gradient of NaCl in 40 mL by mixing Buffer C and 0 to 50% Buffer D (50 mM Tris-HCl, 1 M NaCl, 1 mM DTT, 5% glycerol, pH 7.5) at a 1 mL/min flow rate. Check the eluted protein in different fractions using SDS-PAGE<sup>24</sup>, and pool the fractions containing <sup>TetraCys</sup>Cand1. Note that <sup>TetraCys</sup>Cand1 has a larger retention volume than free GST.

3.3.4. Concentrate the pooled <sup>TetraCys</sup>Cand1 sample by passing the buffer through an ultrafiltration membrane (30 kDa cutoff).

3.3.5. Equilibrate the size exclusion chromatography column with labeling buffer (20 mM Tris-HCl, 100 mM NaCl, 2 mM TCEP, 1 mM EDTA, 5% glycerol) on the FPLC system. Load <sup>TetraCys</sup>Cand1 sample (500 µL each time) and check the eluate fractions by SDS-PAGE<sup>24</sup>.

3.3.6. Pool all the fractions containing <sup>TetraCys</sup>Cand1 and concentrate the protein to ~40 µM by passing the buffer through an ultrafiltration membrane (30 kDa cutoff). Estimate the protein concentration using its absorbance at 280 nm. Store the protein as 50 µL aliquots at -80 °C.

NOTE: The protocol can be paused here.

#### 3.4. Preparation of <sup>FlAsH</sup>Cand1.

3.4.1. Add 1 µL of <sup>FlAsH</sup> solution (see **Table of Materials**) to 50 µL <sup>TetraCys</sup>Cand1 solution.

3.4.2. Mix well and incubate the mixture at room temperature in the dark for 1-2 h to get <sup>FlAsH</sup>Cand1.

NOTE: The protocol can be paused here.

#### 4. Preparation of Cand1, the FRET chase protein

NOTE: The protein preparation protocol is similar to Step 3, with the following modifications.

4.1. Insert the coding sequence of full-length Cand1 into the pGEX-4T-2 vector.

4.2. Change the buffer used in step 3.3.5 to a buffer containing 30 mM Tris-HCl, 100 mM NaCl, 1 mM DTT, 10% glycerol.



4.3. Eliminate steps 3.3.7 and 3.3.8.

## 5. Test and confirm the FRET assay

5.1. Prepare the FRET buffer containing 30 mM Tris-HCl, 100 mM NaCl, 0.5 mM DTT, 1 mg/mL ovalbumin, pH 7.6, and use at room temperature.

5.2. Test the FRET between Cul1<sup>AMC</sup>•Rbx1 and FIA<sup>SH</sup>Cand1 on a fluorimeter.

5.2.1. In 300 µL of FRET buffer, add Cul1<sup>AMC</sup>•Rbx1 (FRET donor) to a final concentration of 70 nM. Transfer the solution into a cuvette.

5.2.2. Place the cuvette in the sample holder of a fluorimeter. Excite the sample with 350 nm excitation light and scan the emission signals from 400 nm to 600 nm at 1 nm increments.

5.2.3. Repeat step 5.2.1 but change Cul1<sup>AMC</sup>•Rbx1 to FIA<sup>SH</sup>Cand1 (FRET acceptor). Scan the FIA<sup>SH</sup>Cand1 sample using the same method as in step 5.2.2.

5.2.4. (Optional) Excite the FIA<sup>SH</sup>Cand1 with 510 nm excitation light, and scan the emission signal from 500 nm to 650 nm.

5.2.5. In 300 µL FRET buffer, add both Cul1<sup>AMC</sup>•Rbx1 and FIA<sup>SH</sup>Cand1 to a final concentration of 70 nM. Analyze the sample in the same way as in step 5.2.2.

5.3. Confirm the FRET between Cul1<sup>AMC</sup>•Rbx1 and FIA<sup>SH</sup>Cand1 by adding the chase (unlabeled Cand1) protein (**Figure 3C**).

5.3.1. In 300 µL of FRET buffer, add 70 nM Cul1<sup>AMC</sup>•Rbx1 and 700 nM Cand1. Scan the sample emission as in step 5.2.2.

5.3.2. In 300 µL of FRET buffer, add 70 nM FIA<sup>SH</sup>Cand1 and 700 nM Cand1. Scan the sample emission as in step 5.2.2.

5.3.3. In 300 µL of FRET buffer, add 70 nM Cul1<sup>AMC</sup>•Rbx1 and 70 nM FIA<sup>SH</sup>Cand1, and incubate the sample at room temperature for 5 min. Then add 700 nM Cand1, and immediately after the addition, scan the sample emission as in step 5.2.2). Note that this step is similar to step 5.2.5.

5.3.4. In 300 µL FRET buffer, sequentially add 70 nM Cul1<sup>AMC</sup>•Rbx1, 700 nM Cand1, and 70 nM FIA<sup>SH</sup>Cand1. Incubate the sample at room temperature for 5 min, and scan the sample emission as in step 5.2.2. Note that this is the chase sample (green line in **Figure 3C**).

## 6. Measure the association rate constant ( $k_{on}$ ) of Cul1•Cand1

NOTE: Details of operating a stopped-flow fluorimeter has been described in a previous report<sup>26</sup>.

### 6.1. Prepare the stopped-flow fluorimeter for measurement.

6.1.1. Turn on the stopped-flow fluorimeter according to the manufacturer's instruction.

6.1.2. Set the excitation light at 350 nm, and use a band-pass filter that allows 450 nm emission light to pass and blocks 500-650 nm emission light.

6.1.3. Keep the sample valves at the **FILL** position, and connect a 3 mL syringe filled with water. Wash the two sample syringes (A and B) with water by moving the sample syringe drive up and down several times. Discard all the water used in this step.

6.1.4. Keep the sample valves at the **FILL** position, and connect a 3 mL syringe filled with FRET buffer. Wash the two sample syringes with the FRET buffer by moving the sample syringe drive up and down several time. Discard all the FRET buffer used in this step.

### 6.2. Take a control measurement (Figure 4C).

6.2.1. Connect a 3 mL syringe and load Syringe A with 100 nM Cul1<sup>AMC</sup>•Rbx1 in the FRET buffer. Turn the sample valve to the **DRIVE** position.

6.2.2. Connect a 3 mL syringe and load Syringe B with the FRET buffer. Turn the sample valve to the **DRIVE** position.

6.2.3. Use the **Control Panel** under **Acquire** in the software to take five shots (mix equal volume of samples from Syringe A and Syringe B) on the stopped-flow fluorimeter without recording the results.

6.2.4. Open the **Control Panel** under **Acquire** in the software, and program to record the emission of Cul1<sup>AMC</sup> over 60 s. Then take a single shot.

6.2.5. Repeat step 6.2.4 2x.

6.2.6. Turn the sample valve to the **FILL** position. Empty Syringe B and wash with the FRET buffer.

### 6.3. Measure observed association rate constants ( $k_{obs}$ ) of Cul1•Cand1 (Figure 4B).

6.3.1. Keep the sample in Syringe A the same as in step 6.2.1.

6.3.2. Connect a 3 mL syringe and load Syringe B with 100 nM FlAsH<sup>Cand1</sup> in the FRET buffer. Turn the sample valve to the **DRIVE** position.

6.3.3. Use the **Control Panel** under **Acquire** in the software to take five shots without recording

the results.

6.3.4. Open the **Control Panel** under **Acquire** in the software, and program to record the emission of Cul1<sup>AMC</sup> over 60 s. Then take a single shot.

6.3.5. Repeat step 6.3.4 2x.

6.3.6. Empty Syringe B and wash with the FRET buffer.

6.3.7. Repeat steps 6.3.1–6.3.6 several times with increasing concentrations of FIA<sup>SH</sup>Cand1 in the FRET buffer.

6.3.8. Fit the change (decrease) in fluorescent signals measured over time from each shot to a single exponential curve. This will give  $k_{obs}$  in each measurement, and the unit is s<sup>-1</sup>. Note that the basis of this calculation has been well discussed in a previous report<sup>27</sup>.

6.4. Calculate the average and standard deviation of  $k_{obs}$  for each FIA<sup>SH</sup>Cand1 concentration used. Plot the average  $k_{obs}$  against Cand1 concentration (**Figure 4D**), and the slope of the line represents the  $k_{on}$  of Cul1•Cand1, with a unit of M<sup>-1</sup> s<sup>-1</sup>.

## 7. Measure the dissociation rate constant ( $k_{off}$ ) of Cul1•Cand1 in the presence of Skp1•F-box protein.

NOTE: This step is similar to Step 6, with the following modifications.

7.1. In Syringe A, under the **FILL** position, load a solution of 100 nM Cul1<sup>AMC</sup>•Rbx1 and 100 nM FIA<sup>SH</sup>Cand1 in the FRET buffer. Turn the sample valve to the “DRIVE” position.

7.2. In Syringe B, under the **FILL** position, load a solution of Skp1•Skp2 (prepared following a previous report<sup>20</sup>). Turn the sample valve to the “DRIVE” position.

7.3. Open the **Control Panel** under **Acquire** in the software, and program to record the emission of Cul1<sup>AMC</sup> over 30 s. Then take a single shot. The fluorescent signals increase over time after mixing solutions from Syringe A and Syringe B (**Figure 5**).

## REPRESENTATIVE RESULTS:

To test the FRET between Cul1<sup>AMC</sup> and FIA<sup>SH</sup>Cand1, we first determined the emission intensity of 70 nM Cul1<sup>AMC</sup> (the donor) and 70 nM FIA<sup>SH</sup>Cand1 (the acceptor), respectively (**Figure 3A–C**, blue lines). In each analysis, only one emission peak was present, and the emission of FIA<sup>SH</sup>Cand1 (the acceptor) was low. When 70 nM each of Cul1<sup>AMC</sup> and FIA<sup>SH</sup>Cand1 were mixed to generate FRET, two emission peaks were present in the emission spectra, and the peak of Cul1<sup>AMC</sup> became lower and the peak of FIA<sup>SH</sup>Cand1 became higher (**Figure 3A–C**, red lines). When the full-length Cand1 was used for FRET, the donor peak showed a 10% reduction in intensity (**Figure 3A**, red line), and when Cand1 with its first helix truncated was used, the reduction of donor peak intensity was

increased to 30% (**Figure 3B–D**, red lines), suggesting higher FRET efficiency. To confirm that the signal changes were resulted from FRET between Cul1<sup>AMC</sup> and <sup>FIAsH</sup>Cand1, 70 nM Cul1<sup>AMC</sup> (the donor) was mixed with 700 nM unlabeled Cand1 (the chase) and 70 nM <sup>FIAsH</sup>Cand1 (the acceptor). As a result, the donor peak was fully restored and the acceptor peak was decreased (**Figure 3C**, green line), which confirmed that the observed FRET depends on the formation of the Cul1<sup>AMC</sup>•<sup>FIAsH</sup>Cand1 complex. Adding 700 nM Skp1•Skp2 to the 70 nM Cul1<sup>AMC</sup>•<sup>FIAsH</sup>Cand1 also fully restored the donor peak (**Figure 3D**, green line), suggesting that the Cul1•Cand1 complex was fully disrupted by Skp1•Skp2 at equilibrium.

[Place **Figure 3** here]

To measure the  $k_{on}$  of Cul1•Cand1 using the established FRET assay by monitoring the reduction of the donor signal over time on the stopped-flow fluorimeter, we first tested and determined the concentration of the protein to be used. When 5 nM each of Cul1<sup>AMC</sup> and <sup>FIAsH</sup>Cand1 were used, very little signal change was observed (**Figure 4A**), whereas, when the concentration of each protein was increased to 50 nM, the reduction of the signal over time was observed (**Figure 4B**) and this change was abolished if buffer without <sup>FIAsH</sup>Cand1 was added (**Figure 4C**). Therefore, 50 nM Cul1<sup>AMC</sup> was used for further analyses, and a series of observed association rate constants ( $k_{obs}$ ) were measured by mixing 50 nM Cul1<sup>AMC</sup> with increasing concentrations of <sup>FIAsH</sup>Cand1. The  $k_{obs}$  for each experiment was calculated by fitting the points to a single exponential curve, and the  $k_{obs}$  obtained from the same <sup>FIAsH</sup>Cand1 concentration were averaged. By plotting the average  $k_{obs}$  with the Cand1 concentration and performing a linear regression (**Figure 4D**), the  $k_{on}$  was determined<sup>7,27</sup>.

[Place **Figure 4** here]

Similar to the measurement of  $k_{on}$ , we measured the observed dissociation rate constant of Cul1•Cand1 by monitoring the increase (restore) of the donor signal over time on the stopped-flow fluorimeter. Cul1<sup>AMC</sup> and <sup>FIAsH</sup>Cand1 were mixed first, and then Skp1•Skp2 was added to the preassembled Cul1<sup>AMC</sup>•<sup>FIAsH</sup>Cand1 on the stopped-flow fluorimeter. The donor signal increased quickly and it revealed a  $k_{obs}$  of 0.4 s<sup>-1</sup> (**Figure 5**). In contrast, when buffer was added to the preassembled Cul1<sup>AMC</sup>•<sup>FIAsH</sup>Cand1, no signal increase was observed, suggesting the fast dissociation of Cul1•Cand1 was triggered by Skp1•Skp2.

[Place **Figure 5** here]

#### FIGURE AND TABLE LEGENDS:

**Figure 1: The crystal structure of Cul1•Cand1 and measurement of the distance between potential labeling sites.** The crystal structure file was downloaded from Protein Data Bank (File 1U6G), and viewed in PyMOL. Measurements between selected atoms were done by PyMOL.

**Figure 2: The excitation and emission spectra of the fluorescent dyes for FRET.** Spectra of AMC (7-amino-4-methylcoumarin) and FIAsH are shown. Dashed lines indicate excitation spectra, and solid lines indicate emission spectra. The image was originally generated by the Fluorescence

SpectraViewer and was modified for better clarity.

**Figure 3: Representative FRET assay for Cul1•Cand1 complex formation.** Samples in the FRET buffer (30 mM Tris-HCl, 100 mM NaCl, 0.5 mM DTT, 1 mg/mL ovalbumin, pH 7.6) were excited at 350 nm, and the emissions were scanned from 400 nm to 650 nm. **(A)** Emission spectra of 70 nM Cul1<sup>AMC</sup>, 70 nM FIA<sup>SH</sup>Cand1 (full), and a mixture of the two (FRET). Cand1 (full) stands for full length Cand1. **(B)** Emission spectra of 70 nM Cul1<sup>AMC</sup>, 70 nM FIA<sup>SH</sup>Cand1, and a mixture of the two (FRET). Cand1 with its first helix deleted was used in this experiment and thereafter. **(C)** Emission spectra of 70 nM Cul1<sup>AMC</sup>, 70 nM FIA<sup>SH</sup>Cand1, a mixture of the two (FRET), and chase control for FRET (Chase). The chase sample contained 70 nM Cul1<sup>AMC</sup>, 700 nM Cand1 and 70 nM FIA<sup>SH</sup>Cand1. **(D)** Emission spectra of 70 nM Cul1<sup>AMC</sup>, a mixture of 70 nM Cul1<sup>AMC</sup> and 70 nM FIA<sup>SH</sup>Cand1 (FRET), and 700 nM Skp1•Skp2 added to the 70 nM Cul1<sup>AMC</sup>•FIA<sup>SH</sup>Cand1 complex. In each plot, the emission signals were normalized to the emission of 70 nM Cul1<sup>AMC</sup> at 450 nm.

**Figure 4: Representative measurement of association rate constant.** **(A)** The fluorescence of 5 nM Cul1<sup>AMC</sup> was monitored by a stopped-flow fluorimeter over time upon addition of 5 nM FIA<sup>SH</sup>Cand1. **(B)** The fluorescence of 50 nM Cul1<sup>AMC</sup> was monitored by a stopped-flow fluorimeter over time upon addition of 50 nM FIA<sup>SH</sup>Cand1. **(C)** The fluorescence of 50 nM Cul1<sup>AMC</sup> was monitored by a stopped-flow fluorimeter over time upon addition of the FRET buffer. **(D)**  $k_{on}$  for Cand1 binding to Cul1.  $k_{obs}$  of Cul1•Cand1 at different concentrations of Cand1 are plotted. Linear slope gives  $k_{on}$  of  $1.8 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$ . Error bars represent  $\pm$ SEM;  $n = 4$ . All samples were prepared in the FRET buffer and excited at 350 nm. A band-pass filter was used to collect signals from AMC and exclude signals from FIA<sup>SH</sup>. No data were normalized.

**Figure 5: Representative measurement of dissociation rate constant.** The change in donor fluorescence versus time was measured following addition of 150 nM Skp1•Skp2 or the FRET buffer to 50 nM Cul1<sup>AMC</sup>•FIA<sup>SH</sup>Cand1 complex. Signal changes were fit to a single exponential curve, and it gives observed dissociation rate constant of  $0.4 \text{ s}^{-1}$ . The experimental conditions were similar to that described in **Figure 4**.

## DISCUSSION:

FRET is a physical phenomenon that is of great interest for studying and understanding biological systems<sup>19</sup>. Here, we present a protocol for testing and using FRET to study the binding kinetics of two interacting proteins. When designing FRET, we considered three major factors: the spectral overlap between donor emission and acceptor excitation, the distance between the two fluorophores, and the dipole orientation of the fluorophores<sup>28</sup>. To choose the fluorophores for FRET, we overlaid the excitation and emission spectra of the fluorophores, and searched for fluorophores whose emission peaks are well separated while the emission spectrum of the donor significantly overlaps with the excitation spectrum of the acceptor (**Figure 2**). To optimize the interfluorophore distance and orientation, we used the crystal structure for assistance, and we primarily considered attaching fluorophores to the protein termini, mainly due to the lower risk of disrupting the protein structure and activity. Because the distance between the N-terminus of Cand1 (Cand1<sup>NTD</sup>) and the C-terminus of Cul1 (Cul1<sup>CTD</sup>) is shorter than the distance between the C-terminus of Cand1 and the N-terminus of Cul1 (**Figure 1**), we decided to label Cand1<sup>NTD</sup> and

Cul1<sup>CTD</sup>. Because we had been able to achieve 80%–90% labeling efficiency of the N-terminus of a protein using the tetracysteine tag<sup>25</sup>, we chose to label Cand1<sup>NTD</sup> with FIAsh through the tetracysteine tag. We initially labeled the Cul1<sup>CTD</sup> with cyan fluorescent protein (CFP), which has a few advantages over AMC. First, it is a genetically encoded fluorescent tag, so it does not require additional labeling process nor steps that purify the labeled fluorescent protein from its unlabeled precursor. Second, CFP is brighter than AMC, and therefore, it offers higher assay sensitivity (see discussion below). Third, CFP has a larger spectrum overlap with FIAsh, potentially yielding more efficient FRET with FIAsh. Despite these advantages, however, CFP protein is much larger than the AMC tag, which may interfere with the protein conformation and the intermolecular interaction. Indeed, we did not observe FRET between Cul1<sup>CFP</sup> and FIAshCand1 in our test, which is likely due to inadequate dipole orientation, or disruption of the Cul1-Cand1 interaction by the CFP tag. We then labeled the Cul1<sup>CTD</sup> with AMC, and we observed FRET between Cul1<sup>AMC</sup> and FIAshCand1. The initial FRET using the full-length Cand1 led to 10% reduction of the donor emission (**Figure 3A**). We further found that by deleting the first helix of Cand1, the distance between Cul1 and Cand1 is shortened from 26.8 Å to 15.5 Å (**Figure 1**), and Cand1 lacking the first helix yielded a much stronger FRET with Cul1, showing 30% reduction of the donor emission peak (**Figure 3B**). In addition, one may improve the FRET efficiency by choosing a donor fluorophore with higher quantum yield and an acceptor fluorophore with a larger extinction coefficient.

A characteristic feature of FRET is that when FRET occurs, the emission of the donor decreases and the emission of the acceptor increases (**Figure 3B**). However, fluorophores may display sensitivity to their environment, and thus, the emission intensity may change when another protein is present, even in the absence of FRET<sup>29</sup>. To confirm that the changed emission we observed is due to FRET between Cul1<sup>AMC</sup> and FIAshCand1, we added 10x excess amount of unlabeled acceptor protein (Cand1) as a chase. The chase converts the emission of the donor and the acceptor back to the normal level (**Figure 3C**), which supports that the changed emissions of Cul1<sup>AMC</sup> and FIAshCand1 depend on protein-protein interaction, and therefore, this result confirms that we established a FRET assay that reports the association and dissociation of Cul1•Cand1. Furthermore, we added Skp1•Skp2 to the preassembled Cul1<sup>AMC</sup>•FIAshCand1 complex, and Skp1•Skp2 is known to be able to disrupt the Cul1-Cand1 interaction<sup>6</sup>. We found that the FRET between Cul1<sup>AMC</sup> and FIAshCand1 disappeared (**Figure 3D**, green line) and the emission spectrum became similar to the emission spectrum of the chase sample (**Figure 3C**, green line), suggesting Cul1<sup>AMC</sup>•FIAshCand1 is dissociated by Skp1•Skp2 and Cul1<sup>AMC</sup> does not display abnormal emission when Skp1•Skp2 is present.

By monitoring the change in donor emission, we can directly observe the association and dissociation of Cul1<sup>AMC</sup>•FIAshCand1 on a stopped-flow fluorimeter. The stopped-flow system works by injecting reactants to a mixing chamber to rapidly mix the reactants, and stopping the flow once the mixed reactants are moved into an observation chamber<sup>5</sup>. The signal detection usually starts 1-2 millisecond (ms) after the mixing, which enables studying interactions that occur on the millisecond timescale. However, when the half-life of the observed reaction is shorter than the time required to mix the reactants on a particular device, this approach is not sensitive enough and is no longer appropriate<sup>30</sup>. Stopped-flow analyses have been used to

determine rate constants ranging  $10^{-6}$ – $10^6$  s<sup>-1</sup> for first-order reactions, and  $1$ – $10^9$  M<sup>-1</sup> s<sup>-1</sup> for second-order reactions<sup>5</sup>. To obtain reliable measurement of the kinetic parameters using the stopped-flow fluorimeter, a significant change of the fluorescent signal between the starting and equilibrium points is necessary. We used the FIA<sup>SH</sup>Cand1 lacking the first helix as the acceptor, because it yields better FRET with Cul1<sup>AMC</sup>, and we tested the concentration of the proteins to be used for measurement. When 5 nM each of Cul1<sup>AMC</sup> and FIA<sup>SH</sup>Cand1 were mixed, no change in Cul1<sup>AMC</sup> signal was observed (**Figure 4A**), suggesting this concentration is insufficient for the measurement. When the protein concentrations were increased to 50 nM, the decrease in Cul1<sup>AMC</sup> signal over time became apparent (**Figure 4B**), and this change does not occur when the acceptor protein was absent (**Figure 4C**). Based on this result, we used Cul1<sup>AMC</sup> at 50 nM concentration to measure the  $k_{on}$  for Cul1•Cand1. The concentration of the donor protein used for measurement can vary when different fluorophores are used. For example, when Cul1 is labeled with CFP, 5 nM of CFP-Cul1 is sufficient for the measurement of  $k_{on}$ <sup>6</sup>. Therefore, the optimal concentration of the protein should be tested for each FRET pair, and in principle, brighter fluorophores allow the use of lower protein concentrations and provide better signal-to-noise ratio<sup>31</sup>.

To study protein-protein interactions by FRET, it requires attaching fluorophores to proteins at appropriate positions without disrupting the protein structure and activity, which potentially limits the use of FRET. In this protocol, we labeled the N-terminus of Cand1 using a tetracysteine tag, which specifically binds the FIA<sup>SH</sup> dye and the FIA<sup>SH</sup> dye becomes fluorescent only after it binds the target protein<sup>32</sup>. We labeled Cul1 using sortase-mediated transpeptidation, which attaches a short peptide carrying a fluorophore to the sortase tag at the C-terminus of Cul1<sup>21, 22</sup>. The labeling efficiency is > 80% with the tetracysteine tag, and almost 100% with the sortase-His<sub>6</sub> tag after removing the unreacted protein using Ni-NTA beads (steps 2.4.3–2.4.4). Both methods add a few amino acids to the target protein, introducing minimal alterations to the protein structure. Similar approaches, such as the transglutaminase recognition sequence (Q-tag)<sup>33</sup> and the ybbR tag<sup>34</sup>, can also be used to label the target protein in a site-specific manner. In addition, photostability of the fluorescent dyes can also limit the use of FRET. Repetitive or long exposure to excitation light can lead to photobleaching of the fluorophore, resulting in inaccurate quantification results<sup>35</sup>. Therefore, the donor and acceptor proteins should be protected from light during the preparation and storage steps. When using FRET to measure events that occur slowly, instead of constantly monitoring the change in donor emission over time, short readings of the donor emission should be taken at longer time intervals and the sample should be kept in the dark during the entire experiment<sup>6</sup>.

Because FRET is sensitive and quantitative, it has become an important tool for studying the interaction between macromolecules. This protocol presents an example of using FRET to study the dynamics of a protein complex in solution. FRET has also been used together with live cell imaging to study molecular interactions in living cells<sup>36</sup>, which is powerful in revealing the dynamics of protein complexes under physiological conditions. Furthermore, FRET can also be used at the single-molecule level to study the real-time dynamics of macromolecular complexes<sup>37,38</sup>, providing insights into the conformational change of the complex. To improve the efficiency and detection of FRET, fluorophores and biosensors with enhanced brightness and

photostability are of great interest, which are actively engineered and studied<sup>28,39</sup>.

#### ACKNOWLEDGMENTS:

We thank Shu-Ou Shan (California Institute of Technology) for insightful discussion on the development of the FRET assay. M.G., Y.Z., and X.L. were funded by startup funds from Purdue University to Y.Z. and X.L.

#### DISCLOSURES:

The authors have nothing to disclose.

#### REFERENCES:

1. Stumpf, M.P.H. et al. Estimating the size of the human interactome. *Proceedings of the National Academy of Sciences of the United States of America*. **105** (19), 6959–64, doi: 10.1073/pnas.0708078105 (2008).
2. Kuzmanov, U., Emili, A. Protein-protein interaction networks: probing disease mechanisms using model systems. *Genome Medicine*. **5** (4), 37, doi: 10.1186/gm441 (2013).
3. Titeca, K., Lemmens, I., Tavernier, J., Eyckerman, S. Discovering cellular protein-protein interactions: Technological strategies and opportunities. *Mass Spectrometry Reviews*. (January), 1–33, doi: 10.1002/mas.21574 (2018).
4. Lapetina, S., Gil-Henn, H. A guide to simple, direct, and quantitative in vitro binding assays. *Journal of Biological Methods*. **4** (1), 62, doi: 10.14440/jbm.2017.161 (2017).
5. Zheng, X., Bi, C., Li, Z., Podariu, M., Hage, D.S. Analytical methods for kinetic studies of biological interactions: A review. *Journal of Pharmaceutical and Biomedical Analysis*. **113**, 163–180, doi: 10.1016/j.jpba.2015.01.042 (2015).
6. Pierce, N.W. et al. Cand1 promotes assembly of new SCF complexes through dynamic exchange of F box proteins. *Cell*. **153** (1), 206–215, doi: 10.1016/j.cell.2013.02.024 (2013).
7. Liu, X., Reitsma, J.M., Mamrosh, J.L., Zhang, Y., Straube, R., Deshaies, R.J. Cand1-Mediated Adaptive Exchange Mechanism Enables Variation in F-Box Protein Expression. *Molecular Cell*. **69** (5), 773–786.e6, doi: 10.1016/j.molcel.2018.01.038 (2018).
8. Zheng, N. et al. Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex. *Nature*. **416** (6882), 703–709, doi: 10.1038/416703a (2002).
9. Kleiger, G., Deshaies, R. Tag Team Ubiquitin Ligases. *Cell*. **166** (5), 1080–1081, doi: 10.1016/j.cell.2016.08.014 (2016).
10. Zheng, J. et al. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. *Molecular Cell*. **10** (6), 1519–1526, doi: 10.1016/S1097-2765(02)00784-0 (2002).
11. Hwang, J.W., Min, K.W., Tamura, T.A., Yoon, J.B. TIP120A associates with unneddylated cullin 1 and regulates its neddylation. *FEBS Letters*. **541** (1–3), 102–108, doi: 10.1016/S0014-5793(03)00321-1 (2003).
12. Min, K.W., Hwang, J.W., Lee, J.S., Park, Y., Tamura, T. aki, Yoon, J.B. TIP120A associates with cullins and modulates ubiquitin ligase activity. *Journal of Biological Chemistry*. **278** (18), 15905–15910, doi: 10.1074/jbc.M213070200 (2003).
13. Goldenberg, S.J. et al. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. *Cell*.



- 119 (4), 517–528, doi: 10.1016/j.cell.2004.10.019 (2004).
14. Chuang, H.W., Zhang, W., Gray, W.M. Arabidopsis ETA2, an apparent ortholog of the human cullin-interacting protein CAND1, is required for auxin responses mediated by the SCF(TIR1) ubiquitin ligase. *Plant Cell*. **16** (7), 1883–1897, doi: 10.1105/tpc.021923 (2004).
15. Feng, S. et al. Arabidopsis CAND1, an Unmodified CUL1-Interacting Protein, Is Involved in Multiple Developmental Pathways Controlled by Ubiquitin/Proteasome-Mediated Protein Degradation. *the Plant Cell Online*. **16** (7), 1870–1882, doi: 10.1105/tpc.021949 (2004).
16. Cheng, Y., Dai, X., Zhao, Y. AtCAND1, a HEAT-repeat protein that participates in auxin signaling in Arabidopsis. *Plant Physiology*. **135** (June), 1020–1026, doi: 10.1104/pp.104.044495 (2004).
17. Lo, S.-C., Hannink, M. CAND1-Mediated Substrate Adaptor Recycling Is Required for Efficient Repression of Nrf2 by Keap1. *Molecular and Cellular Biology*. **26** (4), 1235–1244, doi: 10.1128/MCB.26.4.1235-1244.2006 (2006).
18. Okamoto, K., Sako, Y. Recent advances in FRET for the study of protein interactions and dynamics. *Current Opinion in Structural Biology*. **46**, 16–23, doi: 10.1016/j.sbi.2017.03.010 (2017).
19. Hussain, S.A. An introduction to fluorescence resonance energy transfer (FRET). *arXiv preprint*. arXiv:0908.1815 (2009).
20. Li, T., Pavletich, N.P., Schulman, B.A., Zheng, N. High-level expression and purification of recombinant SCF ubiquitin ligases. *Methods in Enzymology*. **398** (1996), 125–142, doi: 10.1016/S0076-6879(05)98012-9 (2005).
21. Popp, M.W., Antos, J.M., Grotenbreg, G.M., Spooner, E., Ploegh, H.L. Sortagging: A versatile method for protein labeling. *Nature Chemical Biology*. **3** (11), 707–708, doi: 10.1038/nchembio.2007.31 (2007).
22. Antos, J.M., Ingram, J., Fang, T., Pishesha, N., Truttmann, M.C., Ploegh, H.L. Site-Specific Protein Labeling via Sortase-Mediated Transpeptidation. *Current Protocols in Protein Science*. **89**, 15.3.1-15.3.19, doi: 10.1002/cpps.38 (2017).
23. Froger, A., Hall, J.E. Transformation of Plasmid DNA into E. coli Using the Heat Shock Method. *Journal of Visualized Experiments*. doi: 10.3791/253 (2007).
24. Simpson, R.J. SDS-PAGE of Proteins. *Cold Spring Harbor Protocols*. **2006** (1), pdb.prot4313, doi: 10.1101/pdb.prot4313 (2006).
25. Kleiger, G., Saha, A., Lewis, S., Kuhlman, B., Deshaies, R.J. Rapid E2-E3 Assembly and Disassembly Enable Processive Ubiquitylation of Cullin-RING Ubiquitin Ligase Substrates. *Cell*. **139** (5), 957–968, doi: 10.1016/j.cell.2009.10.030 (2009).
26. Biro, F.N., Zhai, J., Doucette, C.W., Hingorani, M.M. Application of Stopped-flow Kinetics Methods to Investigate the Mechanism of Action of a DNA Repair Protein. *Journal of Visualized Experiments*. (37), 2–8, doi: 10.3791/1874 (2010).
27. Patel, J.T., Belsham, H.R., Rathbone, A.J., Friel, C.T. Use of Stopped-Flow Fluorescence and Labeled Nucleotides to Analyze the ATP Turnover Cycle of Kinesins. *Journal of Visualized Experiments*. (92), 1–6, doi: 10.3791/52142 (2014).
28. Bajar, B.T., Wang, E.S., Zhang, S., Lin, M.Z., Chu, J. A guide to fluorescent protein FRET pairs. *Sensors (Switzerland)*. **16** (9), 1–24, doi: 10.3390/s16091488 (2016).
29. Chen, A.K., Cheng, Z., Behlke, M.A., Tsourkas, A. Assessing the sensitivity of commercially available fluorophores to the intracellular environment. *Analytical Chemistry*. **80** (19),

7437–7444, doi: 10.1021/ac8011347 (2008).

30. Lin, C.T., Rorabacher, D.B. Mathematical approach for stopped-flow kinetics of fast second-order reactions involving inhomogeneity in the reaction cell. *Journal of Physical Chemistry*. **78** (3), 305–308, doi: 10.1021/j100596a024 (1974).
31. Toseland, C.P., Geeves, M.A. Rapid Reaction Kinetic Techniques. *Fluorescent Methods for Molecular Motors*. 49–65, doi: 10.1007/978-3-0348-0856-9\_3 (2014).
32. Adams, S.R. et al. New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: Synthesis and biological applications. *Journal of the American Chemical Society*. **124** (21), 6063–6076, doi: 10.1021/ja017687n (2002).
33. Lin, C.W., Ting, A.Y. Transglutaminase-catalyzed site-specific conjugation of small-molecule probes to proteins in vitro and on the surface of living cells. *Journal of the American Chemical Society*. **128** (14), 4542–4543, doi: 10.1021/ja0604111 (2006).
34. Yin, J. et al. Genetically encoded short peptide tag for versatile protein labeling by Sfp phosphopantetheinyl transferase. *Proceedings of the National Academy of Sciences of the United States of America*. **102** (44), 15815–15820, doi: 10.1073/pnas.0507705102 (2005).
35. Diaspro, A., Chirico, G., Usai, C., Ramoino, P., Dobrucki, J. Photobleaching. *Handbook Of Biological Confocal Microscopy*. 690–702, doi: 10.1007/978-0-387-45524-2\_39 (2006).
36. Aoki, K., Kamioka, Y., Matsuda, M. Fluorescence resonance energy transfer imaging of cell signaling from *in vitro* to *in vivo*: Basis of biosensor construction, live imaging, and image processing. *Development, Growth & Differentiation*. **55** (4), 515–522, doi: 10.1111/dgd.12039 (2013).
37. Kilic, S. et al. Single-molecule FRET reveals multiscale chromatin dynamics modulated by HP1 $\alpha$ . *Nature Communications*. **9** (1), doi: 10.1038/s41467-017-02619-5 (2018).
38. Shen, K., Arslan, S., Akopian, D., Ha, T., Shan, S.O. Activated GTPase movement on an RNA scaffold drives co-translational protein targeting. *Nature*. **492** (7428), 271–275, doi: 10.1038/nature11726 (2012).
39. Bajar, B.T. et al. Improving brightness and photostability of green and red fluorescent proteins for live cell imaging and FRET reporting. *Scientific Reports*. **6** (February), 1–12, doi: 10.1038/srep20889 (2016).




Figure 2




Figure 3

[Click here to access/download;Figure;Figure 3.ai](#)




Figure 4

[Click here to access/download;Figure;Figure 4.ai](#)





Figure 5



Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Anion exchange chromatography column	GE Healthcare	17505301	HiTrap Q FF anion exchange
Benchtop refrigerated centrifuge	Eppendorf	2231000511	
BL21 (DE3) Competent Cells	ThermoFisher Scientific	C600003	HiTrap SP Sepharose FF
Calcium Chloride	Fisher Scientific	C78-500	
Cation exchange chromatography column	GE Healthcare	17505401	
Desalting Column	GE Healthcare	17085101	
Floor model centrifuge (high speed)	Beckman Coulter	J2-MC	https://www.thermofisher.
Floor model centrifuge (low speed)	Beckman Coulter	J6-MI	
Fluorescence SpectraViewer	ThermoFisher Scientific		
FluoroMax fluorimeter	HORIBA	FluoroMax-3	
FPLC	GE Healthcare	29018224	
GGGG <sup>AMC</sup> peptide	New England Peptide	custom synthesis	
Glutathione beads	GE Healthcare	17075605	
Glycerol	Fisher Scientific	G33-500	
HEPES	Fisher Scientific	BP310-100	
Isopropyl-β-D-thiogalactoside (IPTG)	Fisher Scientific	15-529-019	
LB Broth	Fisher Scientific	BP1426-500	
Ni-NTA agarose	Qiagen	30210	
Ovalbumin	MilliporeSigma	A2512	
pGEX-4T-2 vector	GE Healthcare	28954550	
Protease inhibitor cocktail	MilliporeSigma	4693132001	Superdex 200 10/300 GL cc
Reduced glutathione	Fisher Scientific	BP25211	
Refrigerated shaker	Eppendorf	M1282-0004	
Rosetta Competent Cells	MilliporeSigma	70953-3	
Size exclusion chromatography column	GE Healthcare	28990944	
Sodium Chloride (NaCl)	Fisher Scientific	S271-500	
Stopped-flow fluorimeter	Hi-Tech Scientific	SF-61 DX2	
TCEP·HCl	Fisher Scientific	PI20490	
Thrombin	MilliporeSigma	T4648	Amicon Ultra-15 Centrifuga
Tris Base	Fisher Scientific	BP152-500	
Ultrafiltration membrane	MilliporeSigma	UFC903008	



3 chromatography column

.com/us/en/home/life-science/cell-analysis/labeling-chemistry/fluorescence-spectraviewer.html

column

ul Filter Units, Ultra-15, 30,000 NMWL

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Using in vitro fluorescence resonance energy transfer to study the dynamics of protein complexes at a millisecond time scale
Author(s):	Melaku Garsamo, Yun Zhou, Xing Liu

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:	Xing Liu	
Department:	Department of Biochemistry	
Institution:	Purdue University	
Title:	Assistant Professor	
Signature:		Date: 8/24/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

## Editorial comments:

1. 3.1.1: Is only one primer used here?


**Response:** We have added the reverse primer sequence.

2. 6: This seems to be one of the principal sections of the protocol (e.g., it's in the summary), but you only have highlighted discontinuous steps and there seems to be some detail lacking; e.g., how exactly do you program the software to take shots? Would it be possible for you to add more detail/highlight more for filming here?

**Response:** Thanks for the comments! We revised the summary to emphasize both the FRET assay and the stopped-flow technique. We intended to put more emphasis on the FRET assay because this is indeed the novel part of our work. We have now included two references (Biro et al., *JoVE*, 2010; Patel et al., *JoVE*, 2014) to help explain the operation of a stopped-flow system and the data analyses. We have also added as many details as we can in Step 6 and 7. Our major consideration is that the protocol of operating a stopped-flow machine highly depends on the brand and model of the equipment, and we are trying to focus on the common steps of our experiment that do not vary from system to system.

The steps we highlighted will form a continuous protocol. Steps we skipped are basically repeating the highlighted ones using different sample solutions, and they would look identical in a film. We now added Step 7 for filming, and although these steps will look the same as Step 6, they aim to measure a different parameter.

Here is a screenshot of the software used to take shots (eg, 6.3.4). We plan to show this in the film.



3. 7.2: Where does the Skp1•Skp2 come from? Please add a reference here regarding its production.

**Response:** We have added the reference.

4. Figure 4: Are exponential fits used here as well?

Response: In Fig 4A-4C, we did not do any fitting (these are to show what raw data one can get and what results are acceptable for analyses). In Fig 4D, we did a linear regression, and the figure legend said “Linear slope gives  $k_{on}$  of  $1.8 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$ ”. Steps for data analysis are described in 6.3.8 and 6.4. We have also revised the “REPRESENTATIVE RESULTS” to explain how to treat the data.

5. Please remove ‘Figure 1’/’Figure 2’/etc. from the Figures themselves.

Response: OK.